Critical parameters for particle-based pulmonary delivery of chemotherapeutics

Targeted delivery of chemotherapeutics through the respiratory system is a potential approach to improve drug accumulation in the lung tumor, while decreasing their negative side effects. However, elimination by the pulmonary clearance mechanisms, including the mucociliary transport system, and inge...

全面介绍

书目详细资料
发表在:Journal of Aerosol Medicine and Pulmonary Drug Delivery
主要作者: 2-s2.0-85048392934
格式: Review
语言:English
出版: Mary Ann Liebert Inc. 2018
在线阅读:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048392934&doi=10.1089%2fjamp.2017.1382&partnerID=40&md5=64f6ca16c122e673253dc164dd6c01f9
实物特征
总结:Targeted delivery of chemotherapeutics through the respiratory system is a potential approach to improve drug accumulation in the lung tumor, while decreasing their negative side effects. However, elimination by the pulmonary clearance mechanisms, including the mucociliary transport system, and ingestion by the alveolar macrophages, rapid absorption into the blood, enzymatic degradation, and low control over the deposition rate and location remain the main complications for achieving an effective pulmonary drug delivery. Therefore, particle-based delivery systems have emerged to minimize pulmonary clearance mechanisms, enhance drug therapeutic efficacy, and control the release behavior. A successful implementation of a particle-based delivery system requires understanding the influential parameters in terms of drug carrier, inhalation technology, and health status of the patient's respiratory system. This review aims at investigating the parameters that significantly drive the clinical outcomes of various particle-based pulmonary delivery systems. This should aid clinicians in appropriate selection of a delivery system according to their clinical setting. It will also guide researchers in addressing the remaining challenges that need to be overcome to enhance the efficiency of current pulmonary delivery systems for aerosols. © Copyright 2018, Mary Ann Liebert, Inc. 2018.
ISSN:19412711
DOI:10.1089/jamp.2017.1382